C-reactive protein but not atrial dysfunction predicts recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function

Objectives Maintenance of sinus rhythm after cardioversion of atrial fibrillation is a major clinical challenge also in patients with preserved left ventricular function. Subclinical inflammation and atrial strain have been recognized as important contributors to atrial fibrillation onset and perpetuation. Aim of the study was to compare the predictive role of C-reactive protein (CRP) and indices of atrial dysfunction in relation to subacute arrhythmic recurrence rate in patients with persistent atrial fibrillation and normal left ventricular ejection fraction (LVEF). Methods We studied 53 patients with a mean LVEF of 58.7 ± 6%. Left atrial diameter and area, left atrial auricle emptying velocity, N-terminal pro-b-type natriuretic peptide (NT-proBNP) and CRP levels were determined few hours before electrical cardioversion. NT-proBNP and CRP levels were also measured 1 h and 3 weeks after cardioversion. Results Subacute atrial fibrillation recurrences were documented in 18 (33.9%) patients. Whereas none of the parameters reflecting atrial dysfunction predicted arrhythmic outcome, higher CRP levels (>3.0 mg/l) were significantly associated with atrial fibrillation recurrences [odds ratio (OR): 1.6; 95% confidence interval (CI): 1.4–2.5; P = 0.031]. No changes in CRP levels were evident after cardioversion independently of underlying rhythm. On the contrary, NT-proBNP levels, which were correlated with left atrial auricle emptying velocity, significantly decreased only in patients who maintained sinus rhythm (from 638 ± 329 to 295 ± 261 pg/ml; P < 0.001). Conclusion The present study demonstrates that in patients with persistent atrial fibrillation and preserved LVEF, CRP level is an independent predictor of atrial fibrillation subacute recurrence rate, whereas none of the indices of atrial dysfunction is associated with arrhythmic outcome. NT-proBNP levels reflect, instead, the hemodynamic alterations secondary to arrhythmia presence.

[1]  H. Neuberger,et al.  Discordant Regulation of CRP and NT‐proBNP Plasma Levels After Electrical Cardioversion of Persistent Atrial Fibrillation , 2006, Pacing and clinical electrophysiology : PACE.

[2]  E. Varol,et al.  Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. , 2006, The American journal of cardiology.

[3]  P. Ellinor,et al.  C-Reactive protein in lone atrial fibrillation. , 2006, The American journal of cardiology.

[4]  E. Watanabe,et al.  High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. , 2006, International journal of cardiology.

[5]  S. Mouly,et al.  Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. , 2006, Archives of internal medicine.

[6]  D. Katritsis Is atrial fibrillation an inflammatory disorder? , 2006, European heart journal.

[7]  G. Lip,et al.  Is atrial fibrillation an inflammatory disorder?: reply , 2006 .

[8]  E. Maltezos,et al.  Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. , 2006, The American journal of cardiology.

[9]  G. Lip,et al.  Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. , 2006, Journal of the American College of Cardiology.

[10]  J. Zarauza,et al.  [Relationship between C-reactive protein level and early recurrence of atrial fibrillation after electrical cardioversion]. , 2006, Revista espanola de cardiologia.

[11]  J. Zarauza,et al.  Relación entre concentraciones de proteína C reactiva y recurrencia precoz de la fibrilación auricular tras cardioversión eléctrica , 2006 .

[12]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[13]  K. Chandrasekaran,et al.  High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. , 2005, Journal of the American College of Cardiology.

[14]  S. Yusuf,et al.  Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. , 2005, Journal of the American College of Cardiology.

[15]  C. Pandozi,et al.  N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. , 2005, Journal of the American College of Cardiology.

[16]  M. Chung,et al.  C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion , 2005, Heart.

[17]  D. Kremastinos,et al.  Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. , 2005, The American journal of cardiology.

[18]  C. Boos Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. , 2004, European heart journal.

[19]  R. D. Murray,et al.  Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. , 2004, The American journal of cardiology.

[20]  B. Wożakowska-Kapłon Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. , 2004, The American journal of cardiology.

[21]  J. Mathew,et al.  A multicenter risk index for atrial fibrillation after cardiac surgery. , 2004, JAMA.

[22]  D. Mark,et al.  B-type natriuretic peptide - a biomarker for all seasons? , 2004, The New England journal of medicine.

[23]  Daniel Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.

[24]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[25]  B. Lévy,et al.  Angiotensin II Angiogenic Effect In Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways , 2002, Laboratory Investigation.

[26]  E. Picano,et al.  Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. , 2002, Journal of the American College of Cardiology.

[27]  Michael R. Rosen,et al.  Pathophysiology and Prevention of Atrial Fibrillation , 2001, Circulation.

[28]  M. Russo,et al.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.

[29]  M. Allessie,et al.  Electrophysiologic mechanisms of perpetuation of atrial fibrillation. , 1996, The American journal of cardiology.

[30]  W. Kannel,et al.  Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.

[31]  J Haaksma,et al.  Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? , 1998, Journal of the American College of Cardiology.

[32]  C-reactive protein; , 2022 .